We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton, Dickinson (BDX) Down 1.3% Since Last Earnings Report
Read MoreHide Full Article
A month has gone by since the last earnings report for Becton, Dickinson and Company (BDX - Free Report) . Shares have lost about 1.3% in that time frame.
Will the recent negative trend continue leading up to its next earnings release, or is BDX due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Recent Earnings
Becton, Dickinson and Company, popularly known as BD, reported first-quarter fiscal 2018 earnings of $2.48 per share, which beat the Zacks Consensus Estimate of $2.40. Adjusted earnings increased 3.9% at constant currency (cc) on a year-over-year basis.
The company reported revenues of $3.08 billion, beating the Zacks Consensus Estimate of $3.05 billion. This represents an increase of 5.4% from the prior-year quarter, or 3.7% at cc.
Segmental Analysis
BD Medical
The BD Medical segment generated revenues of $2.04 billion, up 1.9% at cc on a year-over-year basis.
The segment's result reflects an adverse impact from the change in the U.S. dispensing business model. However, BD Medical witnessed strong performance in the Medication and Procedural Solutions as well as the Diabetes Care and Pharmaceutical Systems units.
Medication and Procedural Solutions registered revenues of $925 million in the BD Medical segment, up 5% year over year at cc.
Diabetes Care reported revenues of $277 million, up 2.2% at cc on a year-over-year basis.
Pharmaceutical Systems reported revenues of $245 million, up 3.7% at cc on a year-over-year basis.
However, Medication Management Solutions reported revenues of $587 million, down 3.4% at cc on a year-over-year basis.
BD Life Sciences
The BD Life Sciences segment generated revenues of $1.05 billion, up 7.3% at cc from the year-ago quarter. The segment's performance indicates strong numbers across the Biosciences, Diagnostic Systems and Preanalytical Systems units.
Preanalytical Systems recorded revenues of $375 million in the first quarter, up 4% at cc on a year-over-year basis.
Diagnostic Systems reported revenues of $381 million, up 12.5% year over year at cc.
Meanwhile, the Biosciences unit registered revenues of $289 million, up 5.3% at cc.
Geographic Results
United States
U.S. revenues were roughly $1.66 billion, up 1.6% on a year-over-year basis.
Within the BD Medical segment, growth in the Medication and Procedural Solutions and Diabetes Care units was offset by declines in the Medication Management Solutions and Pharmaceutical Systems units.
BD Life Sciences segment results within the United States were primarily driven by Diagnostic Systems and Preanalytical Systems units in the reported quarter.
International Revenues
International revenues rose 6.3% to $1.42 billion at cc.
Both BD Medical and BD Life Sciences segment registered strong growth outside the United States. Within the BD Medical segment, growth was driven by strength in the Pharmaceutical Systems unit, aided by impressive results in the Medication and Procedural Solutions and Diabetes Care units.
Guidance
Including the accretion from C. R. Bard acquisition, BD expects fiscal 2018 revenues to increase in the range of 30-31% on a reported basis. However, revenues are expected to grow in the range of 4.5-5.5%.
Notably, revenues are likely to be affected by the change in the U.S. dispensing business model.
The company expects adjusted earnings per share in the range of $10.85-$11.00, up from the previous range of $10.55-$10.65. The current range indicates growth of approximately 15% to 16% on a reported basis, or approximately 12% at cc.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates. There have been three revisions higher for the current quarter compared to two lower.
At this time, BDX has a poor Growth Score of F, however its Momentum is doing a lot better with an A. The stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregte VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate that the stock is more suitable for momentum investors than value investors.
Outlook
Estimates have been broadly trending upward for the stock and the magnitude of these revisions looks promising. Notably, BDX has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Becton, Dickinson (BDX) Down 1.3% Since Last Earnings Report
A month has gone by since the last earnings report for Becton, Dickinson and Company (BDX - Free Report) . Shares have lost about 1.3% in that time frame.
Will the recent negative trend continue leading up to its next earnings release, or is BDX due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Recent Earnings
Becton, Dickinson and Company, popularly known as BD, reported first-quarter fiscal 2018 earnings of $2.48 per share, which beat the Zacks Consensus Estimate of $2.40. Adjusted earnings increased 3.9% at constant currency (cc) on a year-over-year basis.
The company reported revenues of $3.08 billion, beating the Zacks Consensus Estimate of $3.05 billion. This represents an increase of 5.4% from the prior-year quarter, or 3.7% at cc.
Segmental Analysis
BD Medical
The BD Medical segment generated revenues of $2.04 billion, up 1.9% at cc on a year-over-year basis.
The segment's result reflects an adverse impact from the change in the U.S. dispensing business model. However, BD Medical witnessed strong performance in the Medication and Procedural Solutions as well as the Diabetes Care and Pharmaceutical Systems units.
Medication and Procedural Solutions registered revenues of $925 million in the BD Medical segment, up 5% year over year at cc.
Diabetes Care reported revenues of $277 million, up 2.2% at cc on a year-over-year basis.
Pharmaceutical Systems reported revenues of $245 million, up 3.7% at cc on a year-over-year basis.
However, Medication Management Solutions reported revenues of $587 million, down 3.4% at cc on a year-over-year basis.
BD Life Sciences
The BD Life Sciences segment generated revenues of $1.05 billion, up 7.3% at cc from the year-ago quarter. The segment's performance indicates strong numbers across the Biosciences, Diagnostic Systems and Preanalytical Systems units.
Preanalytical Systems recorded revenues of $375 million in the first quarter, up 4% at cc on a year-over-year basis.
Diagnostic Systems reported revenues of $381 million, up 12.5% year over year at cc.
Meanwhile, the Biosciences unit registered revenues of $289 million, up 5.3% at cc.
Geographic Results
United States
U.S. revenues were roughly $1.66 billion, up 1.6% on a year-over-year basis.
Within the BD Medical segment, growth in the Medication and Procedural Solutions and Diabetes Care units was offset by declines in the Medication Management Solutions and Pharmaceutical Systems units.
BD Life Sciences segment results within the United States were primarily driven by Diagnostic Systems and Preanalytical Systems units in the reported quarter.
International Revenues
International revenues rose 6.3% to $1.42 billion at cc.
Both BD Medical and BD Life Sciences segment registered strong growth outside the United States. Within the BD Medical segment, growth was driven by strength in the Pharmaceutical Systems unit, aided by impressive results in the Medication and Procedural Solutions and Diabetes Care units.
Guidance
Including the accretion from C. R. Bard acquisition, BD expects fiscal 2018 revenues to increase in the range of 30-31% on a reported basis. However, revenues are expected to grow in the range of 4.5-5.5%.
Notably, revenues are likely to be affected by the change in the U.S. dispensing business model.
The company expects adjusted earnings per share in the range of $10.85-$11.00, up from the previous range of $10.55-$10.65. The current range indicates growth of approximately 15% to 16% on a reported basis, or approximately 12% at cc.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates. There have been three revisions higher for the current quarter compared to two lower.
Becton, Dickinson and Company Price and Consensus
Becton, Dickinson and Company Price and Consensus | Becton, Dickinson and Company Quote
VGM Scores
At this time, BDX has a poor Growth Score of F, however its Momentum is doing a lot better with an A. The stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregte VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate that the stock is more suitable for momentum investors than value investors.
Outlook
Estimates have been broadly trending upward for the stock and the magnitude of these revisions looks promising. Notably, BDX has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.